MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells
Open Access
- 25 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 31 (7), 805-817
- https://doi.org/10.1038/onc.2011.297
Abstract
MUC16/CA125 is a tumor marker currently used in clinics for the follow-up of patients with ovarian cancer. However, MUC16 expression is not entirely restricted to ovarian malignancies and has been reported in other cancers including breast cancer. Although it is well established as a biomarker, function of MUC16 in cancer remains to be elucidated. In the present study, we investigated the role of MUC16 in breast cancer and its underlying mechanisms. Interestingly, our results showed that MUC16 is overexpressed in breast cancer tissues whereas not expressed in non-neoplastic ducts. Further, stable knockdown of MUC16 in breast cancer cells (MDA MB 231 and HBL100) resulted in significant decrease in the rate of cell growth, tumorigenicity and increased apoptosis. In search of a mechanism for breast cancer cell proliferation we found that MUC16 interacts with the ezrin/radixin/moesin domain-containing protein of Janus kinase (JAK2) as demonstrated by the reciprocal immunoprecipitation method. These interactions mediate phosphorylation of STAT3 (Tyr705), which might be a potential mechanism for MUC16-induced proliferation of breast cancer cells by a subsequent co-transactivation of transcription factor c-Jun. Furthermore, silencing of MUC16 induced G2/M arrest in breast cancer cells through downregulation of Cyclin B1 and decreased phosphorylation of Aurora kinase A. This in turn led to enhanced apoptosis in the MUC16-knockdown breast cancer cells through Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated extrinsic apoptotic pathway with the help of c-Jun N-terminal kinase signaling. Collectively, our results suggest that MUC16 has a dual role in breast cancer cell proliferation by interacting with JAK2 and by inhibiting the apoptotic process through downregulation of TRAIL.Keywords
This publication has 60 references indexed in Scilit:
- MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cellsOncogene, 2010
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- Upregulation of MUC4 in Cervical Squamous Cell Carcinoma: Pathologic SignificanceInternational Journal of Gynecological Pathology, 2009
- Mucin Glycosylation Is Altered by Pro-Inflammatory Signaling in Pancreatic-Cancer CellsJournal of Proteome Research, 2009
- Identification of Aurora-A as a Direct Target of E2F3 during G2/M Cell Cycle ProgressionJournal of Biological Chemistry, 2008
- TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotypeBreast Cancer Research and Treatment, 2008
- Focus on Molecules: Human mucin MUC16Experimental Eye Research, 2008
- The functional contrariety of JNKMolecular Carcinogenesis, 2007
- Different mitochondrial intermembrane space proteins are released during apoptosis in a manner that is coordinately initiated but can vary in durationProceedings of the National Academy of Sciences, 2006
- Cancer Cell CyclesScience, 1996